
Retatrutide (RT3-GLP) 20mg
Triple receptor agonist (GLP-1/GIP/glucagon) — 20mg vial offers a lower cost per mg than the 10mg vial.
In Stock
SKU: ML-RETA-20MG
💰 Volume Discounts:
Buy 3+ vials = 10% off · Buy 5+ vials = 15% off
Retatrutide is an investigational triple receptor agonist that simultaneously targets GLP-1, GIP, and glucagon receptors. Published Phase II clinical trials (NEJM, 2023) have investigated its effects on metabolic markers, body weight, and adipose tissue in controlled trial populations.
The 20 mg Retatrutide Vial offers a full 2-month supply at standard research dosing and a lower cost per mg compared to purchasing two 10 mg vials separately. For in-vitro and laboratory research use only — this is not an approved medication.
Related Products

AOD9604 5mg
Growth hormone fragment for targeted fat reduction — stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or growth.
FeaturedRetatrutide (RT3-GLP) 10mg
Triple receptor agonist studied in clinical research on GLP-1, GIP, and glucagon pathway modulation.

MOTS-C 40mg
Mitochondrial exercise mimetic — AMPK activation, insulin sensitivity, and fat metabolism. Larger dose vial for extended protocols.

Tirzepatide 10mg
Dual GLP-1/GIP receptor agonist — up to 22.5% body weight reduction in trials, the most effective approved weight loss compound to date.